United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, April 17th. The shares were sold at an average price of $586.66, for a total transaction of $5,573,270.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $23,767,356.58. This represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
United Therapeutics Stock Down 2.5%
Shares of NASDAQ:UTHR opened at $573.44 on Tuesday. The stock has a market cap of $25.13 billion, a PE ratio of 20.55, a PEG ratio of 1.68 and a beta of 0.75. The company's fifty day moving average is $528.74 and its 200 day moving average is $491.26. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the prior year, the business posted $6.19 earnings per share. The company's revenue was up 7.4% on a year-over-year basis. Sell-side analysts anticipate that United Therapeutics Corporation will post 27.93 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the business. AE Wealth Management LLC lifted its stake in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company's stock worth $1,798,000 after acquiring an additional 3,424 shares during the period. Great Lakes Advisors LLC increased its position in United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company's stock valued at $1,888,000 after purchasing an additional 2,975 shares during the period. Optimize Financial Inc purchased a new position in United Therapeutics during the 3rd quarter valued at $444,000. Simplify Asset Management Inc. bought a new position in United Therapeutics in the 3rd quarter worth $8,351,000. Finally, Merit Financial Group LLC lifted its position in shares of United Therapeutics by 56.3% in the 3rd quarter. Merit Financial Group LLC now owns 7,416 shares of the biotechnology company's stock worth $3,109,000 after purchasing an additional 2,672 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.
United Therapeutics News Roundup
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Company-reported clinical data to be presented at ISHLT (ARTISAN and PHINDER interim analyses) suggest earlier detection/management benefits in pulmonary hypertension, right-ventricular improvement with high‑dose treprostinil, and broader pipeline visibility including lung donor expansion and xenotransplantation — these findings can support longer-term revenue and pipeline value. United Therapeutics Presents New Data at ISHLT 2026
- Positive Sentiment: Analyst consensus remains constructive — UTHR carries an average recommendation of "Moderate Buy," which can underpin investor confidence and valuation support amid near-term volatility. United Therapeutics Given Average Recommendation of Moderate Buy
- Neutral Sentiment: A comparative valuation piece (CPRX vs UTHR) discusses which is a better value — useful context for value-oriented investors but not company-specific news likely to move the stock materially on its own. CPRX or UTHR: Which Is the Better Value Stock Right Now?
- Neutral Sentiment: Unusually large options trading was reported, indicating elevated short-term interest or hedging activity — this can amplify intraday moves but is ambiguous on direction. United Therapeutics Target of Unusually Large Options Trading
- Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.57M) on April 17 and reduced her stake by ~19% in that filing — large insider sales often trigger investor concern about near-term outlook or personal liquidity needs. SEC Filing - CEO Insider Sale
- Negative Sentiment: Additional recent insider sales reported: CFO sale totaling about $5.77M and a director sale of ~$578.9k — multiple senior-level sales in close succession increase perceived selling pressure. CFO Insider Sale Director Insider Sale
- Negative Sentiment: Earlier small CEO sale (~$40k) was also disclosed — while smaller, it adds to the sequence of insider disposals that investors are noting. CEO Insider Sale (smaller)
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. Wells Fargo & Company raised their price target on United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a research report on Tuesday, March 31st. TD Cowen boosted their price objective on United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research report on Monday, March 30th. Bank of America increased their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research note on Tuesday, March 31st. Raymond James Financial assumed coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 target price on the stock. Finally, Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $601.50.
Read Our Latest Analysis on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
